| Dr Ronald K Law, MD,FACC | |
|
4101 W Conejos Pl, Suite 100, Denver, CO 80204-1377 | |
| (303) 595-2727 | |
| (303) 595-2626 |
| Full Name | Dr Ronald K Law |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 4101 W Conejos Pl, Denver, Colorado |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447256318 | NPI | - | NPPES |
| 01213198 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 21319 (Colorado) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ronald K Law, MD,FACC 4101 W Conejos Pl, Suite 100, Denver, CO 80204-1377 Ph: (303) 595-2727 | Dr Ronald K Law, MD,FACC 4101 W Conejos Pl, Suite 100, Denver, CO 80204-1377 Ph: (303) 595-2727 |
News Archive
Research published in the March issue of the Journal of Thoracic Oncology sought to determine whether differences existed in tolerance and efficacy between patients age 70 and over and younger patients with non-small cell lung cancer (NSCLC) receiving salvage targeted therapy with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) or chemotherapy.
Emisphere Technologies, Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen® Technology. This is the second license agreement between the two companies. The first agreement, for the development of oral formulations of GLP-1 receptor agonists, was signed in June 2008, with a potential drug currently in a Phase I clinical trial.
A new light-based technique for measuring levels of the toxic protein that causes Huntington's disease (HD) has been used to demonstrate that the protein builds up gradually in blood cells. Published today (17th) in the Journal of Clinical Investigation, the findings shed light on how the protein causes damage in the brain, and could be useful for monitoring the progression of HD, or testing new drugs aimed at suppressing production of the harmful protein.
A recent study describes a novel compound with frameshifting capability against MERS-CoV, inhibiting viral propagation within infected cells.
› Verified 9 days ago
Katrina Wagoner-hursh, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1835 Franklin St, Denver, CO 80218 Phone: 303-338-4545 | |
Emily Martin Jones, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 8111 E Lowry Blvd, Denver, CO 80230 Phone: 720-848-0000 | |
Dr. Jesus Heliodoro Hermosillo Rodriguez, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2045 N Franklin St, Denver, CO 80205 Phone: 303-338-4545 | |
Margaret Hay, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1601 E 19th Ave Ste 3100, Denver, CO 80218 Phone: 303-863-0300 Fax: 303-863-7014 | |
Dr. Alan W Burgess, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1601 E 19th Ave Ste 6000, Denver, CO 80218 Phone: 303-861-7001 Fax: 303-861-8624 | |
Dr. Sahibzada Mohsin Shah, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 777 Bannock St, Denver, CO 80204 Phone: 303-436-6000 | |
Shyam M Parkhie, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 130 Rampart Way, 300b, Denver, CO 80230 Phone: 720-343-1562 Fax: 720-343-1563 |